Skip to main content


Medically reviewed by Last updated on Aug 18, 2020.


(doo TAS teer ide)

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Avodart: 0.5 mg

Generic: 0.5 mg

Brand Names: U.S.

  • Avodart

Pharmacologic Category

  • 5 Alpha-Reductase Inhibitor


Dutasteride is a 4-azo analog of testosterone and is a competitive, selective inhibitor of both reproductive tissues (type 2) and skin and hepatic (type 1) 5α-reductase. This results in inhibition of the conversion of testosterone to dihydrotestosterone and markedly suppresses serum dihydrotestosterone levels.


Absorbed via skin when handling capsules


Vd: 300 to 500 L, ~12% of serum concentrations partitioned into semen


Hepatic via CYP3A4 and CYP3A5 isoenzymes (extensive); forms metabolites: 6-hydroxydutasteride has activity similar to parent compound, 4′-hydroxydutasteride and 1,2-dihydrodutasteride are much less potent than parent in vitro


Feces (40% as metabolites, ~5% as unchanged drug); urine (<1% as unchanged drug); ~55% of dose unaccounted for

Time to Peak

2-3 hours

Half-Life Elimination

Terminal: ~5 weeks

Protein Binding

99% to albumin; ~97% to alpha1-acid glycoprotein; >96% to semen protein

Special Populations: Elderly

Dutasteride half-life increases with age.

Use: Labeled Indications

Benign prostatic hyperplasia: Treatment of symptomatic benign prostatic hyperplasia (BPH) as monotherapy (to improve symptoms, reduce the risk of acute urinary retention, and to reduce the risk of need for BPH-related surgery) or combination therapy with tamsulosin

Limitations of use: Not approved for the prevention of prostate cancer.

Off Label Uses

Male pattern baldness

Two randomized, placebo-controlled trials demonstrated efficacy of dutasteride in increased hair growth compared to placebo, with the most common side effect reported was decreased libido or sexual dysfunction [Eun 2010], [Olsen 2006]. In one of the trials, dutasteride 2.5 mg demonstrated superiority to finasteride 5 mg at 12 and 24 weeks; however, androgen-related adverse effects may also occur more frequently with dutasteride due to its potency [Olsen 2006]. Additional trials may be necessary to further define the role of dutasteride in the treatment of this condition.


Clinically significant hypersensitivity to dutasteride, other 5-alpha-reductase inhibitors (eg, finasteride), or any component of the formulation; pregnancy.

Dosing: Adult

Benign prostatic hyperplasia (BPH): Males: Oral: 0.5 mg once daily alone or in combination with tamsulosin

Dosing: Geriatric

Refer to adult dosing.


Oral: May be administered without regard to meals. Capsule should be swallowed whole; do not chew or open; contact with opened capsule can cause oropharyngeal irritation. Should not be touched or handled by women who are pregnant or may be pregnant.


Store at controlled room temperature of 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Drug Interactions

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dutasteride. Monitor therapy

Test Interactions

PSA levels decrease in treated patients. After 3 months of therapy, PSA levels stabilize to a new baseline that is ~50% of pretreatment values. If following serial PSAs in a patient, re-establish a new baseline after ≥3 months of use. If interpreting an isolated PSA value in a patient treated for ≥3 months, then double the PSA value for comparison.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Frequency of most adverse events (except prostate cancer high grade) tends to decrease with continued use (>6 months). Frequency not always defined.

1% to 10%:

Endocrine & metabolic: Decreased libido (≤3%; incidence highest during first 6 months of therapy), gynecomastia (including breast tenderness, breast enlargement; ≤1%), increased luteinizing hormone, increased testosterone level, increased thyroid stimulating hormone level

Genitourinary: Impotence (≤5%; incidence highest during first 6 months of therapy), ejaculatory disorder (≤2%)

Hematologic & oncologic: Prostate cancer high grade (≤1%)

<1%, postmarketing, and/or case reports: Angioedema, cardiac failure, depressed mood, dermatological reaction (serious), dizziness, hypersensitivity, localized edema, malignant neoplasm of breast (males), pruritus, skin rash, testicular pain, testicular swelling, urticaria


Disease-related concerns:

• Diminished urinary flow: Carefully monitor patients with a large residual urinary volume or severely diminished urinary flow for obstructive uropathy; these patients may not be candidates for dutasteride therapy.

• Hepatic impairment: Use with caution in patients with hepatic impairment.

• Prostate cancer: When compared to placebo, 5-alpha-reductase inhibitors (5-ARIs) have been shown to reduce the overall incidence of prostate cancer, although an increase in the incidence of high-grade prostate cancers has been observed; 5-ARIs are not approved in the United States or Canada for the prevention of prostate cancer.

Concurrent drug therapy issues:

• CYP3A4 inhibitors: Use with caution with concurrent use of potent, chronic CYP3A4 inhibitors.

Other warnings/precautions:

• Appropriate use: Other urological diseases, including prostate cancer, should be ruled out before initiating therapy.

• Blood donation: Avoid donating blood during or for 6 months following treatment cessation due to risk of administration to a pregnant female transfusion recipient.

• PSA monitoring: Reduces prostate specific antigen (PSA) by ~50% within 3-6 months of use. If following serial PSAs, re-establish a new baseline ≥3 months after treatment initiation; monitor PSA periodically thereafter. If interpreting an isolated PSA value in a patient treated for ≥3 months, then double the PSA value for comparison to a normal PSA value in an untreated man. PSA increases while on dutasteride should be considered suspicious; obtain serial PSA measurements and evaluate (Andriole, 2006). Patients on a 5-ARI with any increase in PSA levels, even if within normal limits, should be evaluated; may indicate presence of prostate cancer.

Monitoring Parameters

Objective and subjective signs of relief of benign prostatic hyperplasia, including improvement in urinary flow, reduction in symptoms of urgency, and relief of difficulty in micturition; for serial PSA monitoring, establish a new baseline PSA level after 3 months of therapy and monitor PSA periodically thereafter.

Reproductive Considerations

Dutasteride can be detected in semen; sperm count, semen volume, and sperm movement may be decreased, but the effect on male fertility is unknown.

Pregnancy Considerations

Based on the mechanism of action and data from animal reproduction studies, in utero exposure to dutasteride may cause fetal harm. Use is contraindicated in pregnant women.

Capsules should not be handled by pregnant women or women who may be pregnant; if contact with a leaking capsule occurs, wash area immediately with soap and water.

Patient Education

What is this drug used for?

• In men, it is used to treat the signs of an enlarged prostate.

• It may be given to you for other reasons. Talk with the doctor.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Dizziness

• Sexual dysfunction

• Decreased sex drive

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Lump in breast

• Breast pain or soreness

• Nipple discharge

• Enlarged breasts

• Depression

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine’s uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.